Skip to main content
. Author manuscript; available in PMC: 2013 Jun 3.
Published in final edited form as: Gynecol Oncol. 2011 Jun 17;122(3):521–526. doi: 10.1016/j.ygyno.2011.04.041

Table 1.

GOG protocols and study population.

GOG protocol no. Original study eligibility Current study eligibility Treatment regimen No. of patients eligible
114 Optimal (≤ 1-cm residual), stage III EOC Microscopic residual, stage III EOC IV paclitaxel 135 mg/m2, cisplatin 75 mg/m2, × six cycles 81
158 Optimal (≤ 1-cm residual), stage III EOC Microscopic residual, stage III EOC IV paclitaxel 135 mg/m2, cisplatin 75 mg/m2, × six cycles or IV paclitaxel 175 mg/m2(3 h), carboplatin AUC 7.5, × six cycles 281
172 Optimal (≤ 1-cm residual), stage III EOC/PPC Microscopic residual, stage III EOC IV paclitaxel 135 mg/m2, cisplatin 75 mg/m2, × six cycles 75

Abbreviations: GOG, Gynecologic Oncology Group; EOC, epithelial ovarian cancer; IV, intravenously; AUC, area under the curve; PPC, primary peritoneal carcinoma.